U.S., Oct. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07211659) titled 'Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients' on Oct. 01.
Brief Summary: The goal of this clinical trial is to establish if THEO-260 is safe to administer to adult females with ovarian cancer. It will also aim to establish if THEO-260 is able to treat ovarian cancer. The main questions it aims to answer are:
* What medical problems do participants have when taking THEO-260?
* At what dose is THEO-260 both safe but also shows signs of being able to treat ovarian cancer?
The clinical trial follows a dose escalation/ finding design where we will aim to establish a Recommended Phase 2 Dose (RP2...